On 18 June 2026 the Medicines and Healthcare products Regulatory Agency (MHRA), the Advertising Standards Authority (ASA) and the General Pharmaceutical Council (GPhC) issued a joint warning to businesses that promote weight-management medicines in the UK. The three bodies set out one position: the advertising rules apply to medicines before and after authorisation, and promoting an unlicensed or not-yet-authorised product to the public is not permitted.
The warning identified three recurring patterns. Businesses were promoting pipeline products — newer oral and injectable weight-management medicines still under regulatory review — and building consumer waiting lists for them. They were advertising newly licensed oral GLP-1 medicines, which are prescription-only. And they were using shorthand such as 'GLP-1 tablets', 'oral GLP-1s' and 'the new weight-loss tablets' to name products that may not be advertised to the public.
What the rules require
Under the Human Medicines Regulations 2012, a medicinal product may not be advertised to the public unless a UK marketing authorisation is in force, and prescription-only medicines may not be advertised to the public at all. The CAP Code, which governs UK advertising, mirrors that requirement: medicines must hold an MHRA licence before they are marketed. Julian Beach, the MHRA's Executive Director for Healthcare Quality and Access, said the Regulations 'prohibit the advertisement of a medicinal product for which there is no Marketing Authorisation in force', and that creating consumer demand for a product before its UK safety, quality and efficacy appraisal is complete is not permitted.
Why it matters for research compounds
The warning sits alongside, and broadens, the MHRA's April 2026 investigation into UK peptide clinics. In that action the agency's position was that where a clinic makes medicinal claims, the products become medicines under the Human Medicines Regulations 2012 and attract full regulatory oversight — and that a 'research purposes' label will not be accepted where it is being used to circumvent those rules.
For compounds sold as laboratory reagents, the boundary is set by promotion, not by the label alone. A product described purely as a research reagent, with no medicinal claim and no route to human use, remains a research reagent. A product promoted by name for weight management, or offered through a waiting list, is being advertised as a medicine, and the advertising rules apply. That is the same boundary the MHRA draws when it assesses whether a product is a medicine.
The compound position
None of the peptides discussed in this context holds a UK marketing authorisation as a research peptide for human use. Retatrutide remains investigational, with no marketing authorisation in any jurisdiction. Semaglutide and tirzepatide are licensed prescription-only medicines in the UK for defined indications, and as prescription-only products they may not be advertised to the public. Peptide Data describes research findings and regulatory status only; nothing here is consumption, dosing or self-administration guidance, and no therapeutic outcome is claimed. Research use only.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.